In September 2026, a 10% holder, Ching Hang Shen, bought 878,734 shares, and another major shareholder, Eliyahou Et Al Harari, purchased 1,757,469 shares for approximately $10 million. The company also announced participation in upcoming investor conferences and raised $18 million through a direct stock offering to existing shareholders, including Star One Global Capital Limited and Eliyahou Harari, selling 3,163,444 shares at $5.69 each. In August 2026, CapsoVision reported its second-quarter 2026 financial results, which led to a -4.86% stock movement, as the company reported a wider-than-expected loss of $0.15 per share on $3.64 million in revenue, missing analyst expectations, despite 10% year-over-year revenue growth. The company also announced the international launch of AI Highlights, an AI-assisted reading feature for CapsoCam Plus, which was anticipated to receive FDA clearance by the end of Q3 2026 for the U.S. market, with Roth Capital resuming coverage with a 'Buy' rating and Benchmark reaffirming a 'speculative buy' rating. In July 2026, insider Britt Harari bought US$102k worth of shares at US$7.35 per share, while insider Joanne Imperial sold shares worth US$8.6k. In May 2026, CapsoVision reported its first-quarter 2026 financial results, showing steady first-quarter revenue but missing EPS forecasts, which led to a stock rise, and Benchmark reiterated a 'Speculative Buy' rating with a $10.00 price target. In March 2026, CapsoVision published its Q4 2025 annual report, and Benchmark cut its price target to $10 from $14 due to a delayed timeline.
